Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

8.24EUR
11 Dec 2017
Change (% chg)

€-0.08 (-0.96%)
Prev Close
€8.32
Open
€8.35
Day's High
€8.37
Day's Low
€8.14
Volume
410,570
Avg. Vol
495,045
52-wk High
€16.88
52-wk Low
€7.28

Select another date:

BRIEF-Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis

* ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS

BRIEF-Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza‍​

* ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA‍​

BRIEF-Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​

* ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​ Source text for Eikon:

Spain's Almirall warns of delay in approval for psoriasis drug

Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

Spain's Almirall warns of delay in approval for psoriasis drug

Nov 14 Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

BRIEF-Almirall 9-month net result turns to loss of 99.7 mln euros YoY

* 9-MONTH EBITDA 100.1 MILLION EUROS VERSUS 183.8 MILLION EUROS YEAR AGO

BRIEF-Almirall ends phase III research for nail psoriasis product in Europe

* TERMINATES ITS RESEARCH ACTIVITIES FOR P3073 PROGRAM (NAIL PSORIASIS) IN EUROPE IN PHASE III OF DEVELOPMENT ‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Almirall: study confirms efficacy of Sativex in treating multiple sclerosis spasticity

* SAYS STUDY CONFIRMS EFFICACY AND TOLERABILITY OF SATIVEX IN TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY RESISTANT PATIENTS Source text: http://bit.ly/2yPWT4P Further company coverage: (Gdynia Newsroom)

BRIEF-Almirall ends research for two products in US

* SAYS DECIDED TO TERMINATE ITS RESEARCH ACTIVITIES FOR P3058 (ONYCHOMYCOSIS) AND P3073 (NAIL PSORIASIS) IN THE US

BRIEF-Almirall announces phase III positive Duaklir results for COPD

* SAYS PHASE III STUDY SHOWS DUAKLIR SIGNIFICANTLY IMPROVES LUNG FUNCTION IN MODERATE TO VERY SEVERE STABLE COPD

Select another date: